Bronchial asthma: novel therapeutic approaches

Dynamics of Immunological Indices in the Exhaled Air Condensate in Patients with Bronchial Asthma on the Background of Pathogenetic Therapy with the Use of L-Arginine

“…Bronchial asthma is a severe chronic respiratory disease and represents a major public health problem [1]. At present, cardiovascular effects are considered as systemic manifestations of asthma, among which endothelial dysfunction appears as the primary link of the vessel wall damage [2].…”

“…Many of the effects of arginine are due to the fact that it is the pre-agent of NO (donor) produced by endothelial cells of the vessels, macrophages and neutrophils [8]. BA as a complex chronic inflammatory disease involves many structural cells and inflammatory cells, followed by the release of inflammatory mediators, which lead to the formation of the main pathophysiological mechanisms of the disease [1,6]. At present, about 50 cytokines and chemokines are known to play an important role in the pathogenesis of asthma [7], but their role in the management of pathophysiological processes has not been fully understood.…”

“…Investigation of markers of inflammation in the lungs is usually carried out by taking material using bronchoalveolar lavage (BAL), bronchobiopsy [8], as well as serum and urine to assess systemic effects. However, the production of BALF and bronchobiocytes are invasive, traumatic methods that cause multiple side effects, which cannot be carried out in a short time, as well as in severe patients, children and in outpatient practice [1,2]. In recent years, non-invasive methods for diagnosis and control of asthma treatment have been widely introduced into clinical practice, in particular, the study of biomarkers in the exhaled air condensate [5].…”